Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Keith S. Kanik
An Integrated Analysis of the Safety of Tofacitinib in Psoriatic Arthritis Across Phase III and Long-Term Extension Studies With Comparison to Real-World Observational Data
Drug Safety
Toxicology
Pharmacology
Related publications
SAT0439 Integrated Safety Summary of Tofacitinib in Psoriatic Arthritis Clinical Studies
Tofacitinib, an Oral Janus Kinase Inhibitor, for the Treatment of Chronic Plaque Psoriasis: Long-Term Efficacy and Safety Results From 2 Randomized Phase-Iii Studies and 1 Open-Label Long-Term Extension Study
Journal of the American Academy of Dermatology
Dermatology
Tofacitinib: Efficiency and Safety in Long-Term Use
Medical Council
Tofacitinib for the Treatment of Psoriasis and Psoriatic Arthritis
Expert Review of Clinical Immunology
Allergy
Immunology
Real-World Burden of Comorbidities in US Patients With Psoriatic Arthritis
RMD Open
Rheumatology
Allergy
Immunology
Long-Term Survival of Methotrexate in Psoriatic Arthritis
Reumatismo
Rheumatology
Long-Term Safety and Tolerability of Oral Tofacitinib in Patients With Crohn’s Disease: Results From a Phase 2, Open-Label, 48-Week Extension Study
Alimentary Pharmacology and Therapeutics
Hepatology
Pharmacology
Gastroenterology
Real-World Data on Secukinumab Use for Psoriatic Arthritis and Ankylosing Spondylitis
Therapeutic Advances in Musculoskeletal Disease
Rheumatology
Orthopedics
Sports Medicine
Safety and Efficacy of Tofacitinib for Up to 9.5 Years in the Treatment of Rheumatoid Arthritis: Final Results of a Global, Open-Label, Long-Term Extension Study
Arthritis Research & Therapy
